High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Top Cited Papers
Open Access
- 1 January 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 2 (1), 82-93
- https://doi.org/10.1158/2159-8290.cd-11-0184
Abstract
Knowledge of “actionable” somatic genomic alterations present in each tumor (e.g., point mutations, small insertions/deletions, and copy-number alterations that direct therapeutic options) should facilitate individualized approaches to cancer treatment. However, clinical implementation of systematic genomic profiling has rarely been achieved beyond limited numbers of oncogene point mutations. To address this challenge, we utilized a targeted, massively parallel sequencing approach to detect tumor genomic alterations in formalin-fixed, paraffin-embedded (FFPE) tumor samples. Nearly 400-fold mean sequence coverage was achieved, and single-nucleotide sequence variants, small insertions/deletions, and chromosomal copynumber alterations were detected simultaneously with high accuracy compared with other methods in clinical use. Putatively actionable genomic alterations, including those that predict sensitivity or resistance to established and experimental therapies, were detected in each tumor sample tested. Thus, targeted deep sequencing of clinical tumor material may enable mutation-driven clinical trials and, ultimately, “personalized” cancer treatment. Significance: Despite the rapid proliferation of targeted therapeutic agents, systematic methods to profile clinically relevant tumor genomic alterations remain underdeveloped. We describe a sequencing-based approach to identifying genomic alterations in FFPE tumor samples. These studies affirm the feasibility and clinical utility of targeted sequencing in the oncology arena and provide a foundation for genomics-based stratification of cancer patients. Cancer Discovery; 2(1); 82–93. ©2011 AACR. Read the Commentary on this article by Corless and Spellman, p. 23 This article is highlighted in the In This Issue feature, p. 1Other Versions
This publication has 54 references indexed in Scilit:
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation CarriersThe New England Journal of Medicine, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Gene products of chromosome 11q and their association with CCND1gene amplification and tamoxifen resistance in premenopausal breast cancerBreast Cancer Research, 2008
- Identification of genetic variants using bar-coded multiplexed sequencingNature Methods, 2008
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast CancerCancer Cell, 2007
- Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancerOncogene, 2007
- High-throughput oncogene mutation profiling in human cancerNature Genetics, 2007
- Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanomaNature, 2005
- Loss of Smad Signaling in Human Colorectal Cancer Is Associated with Advanced Disease and Poor PrognosisThe Cancer Journal, 2003
- Human breast cancer MDA-MB-231 cells fail to express the neurofibromin protein, lack its type I mRNA isoform and show accumulation of P-MAPK and activated RasCancer Letters, 2001